Nikolaos Nikolaou
BSc (Hons), MSc (Distinction), DPhil
Postdoctoral Researcher
I obtained a BSc (Hons) in Biology from the University of Patras (2011), followed by an MSc in Female Reproduction (Distinction) from the National and Kapodistrian University of Athens, Greece in 2013. During my MSc studies, I received a prestigious MSc Scholarship from the Medical School, University of Athens to fulfil my research project at the University of Birmingham, UK and the Centre for Diabetes, Endocrinology and Metabolism (CEDAM). In 2014, I moved to the University of Oxford to complete my DPhil training under the leadership of Prof. Jeremy Tomlinson. Currently, I am working as a Postdoctoral Researcher under a programme of research funded by the Medical Research Council (MRC), investigating the role of steroid metabolome in the pathogenesis of non-alcoholic fatty liver disease (NAFLD).
My research focuses on the role of pre-receptor regulation of steroid hormone action through manipulation of expression/activity of the A-ring reductases (5α-reductase and 5β-reductase), which have the ability to regulate steroid hormone availability within human liver. Steroid hormones, including glucocorticoids, androgens and oestrogens are potent regulators of metabolic phenotype. Glucocorticoid excess has been associated with hepatic steatosis, and glucocorticoid metabolism is dysregulated across the NAFLD disease spectrum. My work tests the hypothesis that manipulation of expression and activity of these enzymes can regulate aspects of the metabolic phenotype and may represent novel targets for pharmaceutical approach. The techniques I employ include human hepatocyte cell culture, gene editing and expression, western blotting, biochemical analyses, mass-spectrometry and high-throughput enzyme assays.
Key publications
-
The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies
Journal article
NIKOLAOU N. et al, (2021), The Journal of Steroid Biochemistry and Molecular Biology, 105808 - 105808
-
AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease
Journal article
Nikolaou N. et al, (2019), Metabolism, 153947 - 153947
-
AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells.
Journal article
Nikolaou N. et al, (2019), J Steroid Biochem Mol Biol, 189, 218 - 227
-
Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo.
Journal article
Nikolaou N. et al, (2020), J Endocrinol
Recent publications
-
A machine learning approach for multimodal data fusion for survival prediction in cancer patients.
Journal article
Nikolaou N. et al, (2025), NPJ Precis Oncol, 9
-
Towards a survival risk prediction model for metastatic NSCLC patients on durvalumab using whole-lung CT radiomics.
Journal article
Patwardhan KA. et al, (2024), Front Immunol, 15
-
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept, randomized double-blind placebo-controlled trial
Journal article
TOMLINSON J., (2023), Nature Communications
-
Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents.
Journal article
Hazlehurst JM. et al, (2022), Metabol Open, 14

